Nasdaq GEHC Financials Overview and Analysis

The Nasdaq GEHC financials are a crucial aspect of the company's overall performance. GEHC's market capitalization is approximately $100 billion.

GEHC's revenue has consistently grown over the years, with a significant increase in 2020. This growth can be attributed to the company's strong presence in the healthcare industry.

The company's net income has also seen a substantial rise, reaching $2.5 billion in 2020. This increase in profitability is a testament to GEHC's effective management and strategic business decisions.

GEHC's stock price has fluctuated over the years, but it has generally trended upwards, with a significant spike in 2020. This growth in stock price is a positive indicator for investors.

Suggestion: Gehc Earnings

The dividend and shareholder information for NASDAQ GEHC is quite interesting. The company has a dividend yield of 0.14%, which is lower than the industry average.

GEHC's dividend payout ratio is a mere 0.03%, indicating that the company is retaining most of its earnings to reinvest in the business. This is a common strategy for companies looking to grow their operations.

Explore further: Gehc Dividend

The forward dividend yield is expected to be 0.16%, which is slightly higher than the current yield. This suggests that investors can expect a modest increase in dividend payments in the future.

Here's a quick rundown of the dividend and shareholder yield metrics:

The Dividend & Buy Back section of a company's financial information is a crucial aspect to consider for investors.

A dividend yield of 0.14% indicates that the company pays out a relatively small portion of its earnings to shareholders.

The dividend payout ratio of 0.03% suggests that the company retains most of its earnings, which can be used for growth or debt repayment.

A forward dividend yield of 0.16% implies that the company may increase its dividend payment in the future.

The 5-year yield-on-cost of 0.14% shows that the company's dividend yield has remained relatively stable over time.

Shareholder yield, on the other hand, can be negative (-0.2%), which may indicate that the company is currently buying back its own shares rather than paying dividends.

GE Healthcare Technologies Inc. has completed a Follow-on Equity Offering, indicating that the company is healthy and financially stable.

This is a positive sign for investors, as it suggests that the company has a strong financial foundation.

The company's net debt to equity ratio is 65.7%, which is considered high, but its interest payments on debt are well covered by earnings before interest and taxes (EBIT), with a 7.5x coverage.

GE Healthcare's operating cash flow is not sufficient to cover its debt, with a debt coverage ratio of 19.4%.

GEHC's financial health is a mixed bag. Its debt-to-equity ratio is a staggering 107.67%, indicating a significant amount of debt. This is a major red flag, as high debt levels can make a company vulnerable to financial shocks.

GEHC's cash flow situation is not ideal. The company's levered free cash flow is $1.58B, but its debt coverage is only 19.4%, which means its debt is not well covered by operating cash flow.

In terms of interest coverage, GEHC's interest payments on its debt are well covered by EBIT, with a coverage ratio of 7.5x. This is a positive sign, as it indicates that the company has sufficient earnings to cover its interest expenses.

Here's a summary of GEHC's financial health criteria:

Overall, GEHC's financial health is a concern, and the company may need to take steps to reduce its debt levels and improve its cash flow situation.

GE HealthCare Technologies Inc. is a company that specializes in developing, manufacturing, and marketing products and services for the healthcare industry.

The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).

GE HealthCare Technologies Inc. offers a wide range of products, including molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, and X-ray systems.

The company's Imaging segment provides products for women's health, cardiovascular, and comprehensive care ultrasound, as well as surgical visualization and guidance products.

GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022.

GE HealthCare Technologies has a debt-to-equity ratio of 103.2%, which is considered high, and its short term assets ($11.3B) exceed its short term liabilities ($9.7B).

Its interest coverage ratio is 7.5, indicating that its interest payments on its debt are well covered by EBIT. GE HealthCare Technologies's debt coverage by operating cash flow is 19.4%, which is relatively low.

Here are some key financial metrics for GE HealthCare Technologies:

Its 3-year revenue growth rate is 4.2%, and its 3-year FCF growth rate is 6%, indicating some growth in these areas. However, its 3-year book growth rate is -21.5%, showing a decline in this area.

Growth Rank is a crucial aspect of financial analysis, and it's essential to understand the different growth rates to make informed decisions.

The 3-Year Revenue Growth Rate is 4.2, which is a relatively strong growth rate.

A growth rate of 4.2 indicates that the company's revenue has increased by 4.2% over the past three years.

To put this into perspective, a 4.2% growth rate is significantly higher than the industry average.

Here's a breakdown of the growth rates:

The Future 3-5Y Total Revenue Growth Rate Estimate is 3.08, which suggests a moderate growth rate over the next few years.

A growth rate of 3.08 indicates that the company's revenue is expected to increase by 3.08% over the next three to five years.

GE HealthCare Technologies Inc. has a total shareholder equity of $10.0B and total debt of $10.3B, which brings its debt-to-equity ratio to 103.2%. This is a significant concern, as it indicates that the company's debt is significantly higher than its equity.

GEHC's short term assets ($11.3B) exceed its short term liabilities ($9.7B), indicating that the company has sufficient liquidity to meet its short-term obligations. However, its short term assets do not cover its long term liabilities ($15.8B), which suggests that the company may face challenges in meeting its long-term debt obligations.

GEHC's interest payments on its debt are well covered by EBIT (7.5x coverage), which is a positive sign. However, its debt is not well covered by operating cash flow (19.4%), indicating that the company may struggle to meet its debt obligations in the future.

Here is a summary of GEHC's financial position:

As you can see, GEHC has a significant amount of cash on hand, but its debt-to-equity ratio is extremely high. This suggests that the company may need to take steps to reduce its debt levels in order to improve its financial position.

GEHC's valuation measures are worth examining, especially considering its market performance. As of 10/16/2025, its trailing total returns may include dividends or other distributions, making it a good idea to check the S&P 500 (^GSPC) benchmark for comparison.

The company's market capitalization is $35.07B, while its enterprise value is $42.05B. This suggests a significant difference between the two metrics.

Here's a breakdown of GEHC's valuation measures:

The three-year return is a key performance metric that investors should consider when evaluating a company's valuation. GEHC's trailing total returns as of 10/16/2025 include dividends or other distributions.

GEHC's performance is benchmarked against the S&P 500 (^GSPC), a widely followed stock market index.

Valuation Measures are a crucial aspect of evaluating a company's performance. Market Cap is a significant metric, standing at 35.07B.

The Enterprise Value, which includes debt and cash, is 42.05B. This gives us a more comprehensive view of the company's worth.

A Trailing P/E of 15.74 indicates that investors are willing to pay 15.74 times the company's past earnings. This is a relatively reasonable valuation.

Looking ahead, the Forward P/E is 16.69, suggesting a slight increase in valuation. The PEG Ratio (5yr expected) is 3.50, which may indicate that the stock is overvalued.

The Price/Sales ratio is 1.77, indicating that the stock is relatively cheap compared to its sales. The Price/Book ratio is 3.61, suggesting that the stock is somewhat overvalued.

Here are some key valuation metrics at a glance: